Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization ...

That spurred three of the four leading inhaler companies (GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim) to announce in March 2024, that they would cap out-of-pocket costs at $35 per inhaler.

About 69% of hospitalized COPD patients misused inhalers, 66% made critical errors during inhaler use, and 14% had insufficient PIF. An average of 1.4 and 1.3 and critical errors for every inhaler ...

The FDA approved the generic version, Wixela Inhub (fluticasone-salmeterol; Viatris), as the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD) in 2019 ...

Crude incidence of first moderate-to-severe COPD exacerbation was 435 and 410 events per 1,000 person-years for the branded and generic groups, respectively, the bulk of which were moderate cases ...

The researchers found that the incidence of a first moderate or severe COPD exacerbation was higher in patients who received budesonide-glycopyrrolate-formoterol (hazard ratio [HR], 1.09; [95% CI ...

Current chronic obstructive pulmonary disease (COPD) management programs and guidelines overdiagnose elderly patients and underdiagnose young ones. An analysis published online July 1 in the BMJ ...

Baldomero AK, Kunisaki KM, Wendt CH, et al. Guideline-discordant inhaler regimens after COPD hospitalization: associations with rurality, drive time to care, and fragmented care - a United States ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD ...

A 2017 study looked at around 2,600 Medicare Part D and Medicare Advantage plans to determine the average out-of-pocket costs for COPD inhalers. Depending on the inhaler type, costs ranged from ...